Compare KWR & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KWR | SUPN |
|---|---|---|
| Founded | 1918 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 1985 | 2012 |
| Metric | KWR | SUPN |
|---|---|---|
| Price | $143.46 | $51.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $149.25 | $61.60 |
| AVG Volume (30 Days) | 136.7K | ★ 690.1K |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,864,242,000.00 | $681,539,000.00 |
| Revenue This Year | $3.44 | $8.32 |
| Revenue Next Year | $4.15 | $23.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.08 | ★ 4.54 |
| 52 Week Low | $95.91 | $29.16 |
| 52 Week High | $148.80 | $57.65 |
| Indicator | KWR | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 67.03 |
| Support Level | $136.34 | $47.98 |
| Resistance Level | $146.16 | $52.11 |
| Average True Range (ATR) | 4.45 | 1.49 |
| MACD | 0.77 | 0.74 |
| Stochastic Oscillator | 81.78 | 89.49 |
Quaker Houghton manufactures and sells a variety of industrial process fluids. The product portfolio of the company includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids and surface treatment chemicals. The geographic segments of the company include America, EMEA, Asia/Pacific, and Global Specialty Businesses. The majority of the revenue is earned from America.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.